Nishio Shin
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan.
J Obstet Gynaecol Res. 2023 Apr;49(4):1106-1113. doi: 10.1111/jog.15578. Epub 2023 Feb 9.
This article reviews the findings of clinical studies on gastric-type adenocarcinoma of the cervix to date, outline the molecular biological features identified in recent studies, and discusses the future therapeutic strategies. Gastric-type adenocarcinoma of the cervix is a new classification in the World Health Organization 2014 classification. The World Health Organization 2020 classification further divides cervical tumors into two categories: human papillomavirus-associated and human papillomavirus-independent. Thus, gastric-type adenocarcinoma of the cervix is now classified as a human papillomavirus-independent gastric type. Clinical studies have reported that gastric adenocarcinoma of the cervix is refractory to conventional chemotherapy and radiotherapy, and it is desirable to elucidate its molecular biological mechanism. A series of gene mutations characteristic to the gastric-type adenocarcinoma of the cervix encourage the development of future treatment strategies.
本文回顾了迄今为止关于宫颈胃型腺癌的临床研究结果，概述了近期研究中发现的分子生物学特征，并讨论了未来的治疗策略。宫颈胃型腺癌是世界卫生组织2014年分类中的一种新分类。世界卫生组织2020年分类进一步将宫颈肿瘤分为两类：人乳头瘤病毒相关型和人乳头瘤病毒非相关型。因此，宫颈胃型腺癌现在被归类为人乳头瘤病毒非相关型胃型。临床研究报告称，宫颈胃型腺癌对传统化疗和放疗具有耐药性，因此有必要阐明其分子生物学机制。宫颈胃型腺癌特有的一系列基因突变推动了未来治疗策略的发展。
